Bica Cecilia, Jurj Ancuta, Harangus Antonia, Ciocan Cristina, Moldovan Alin, Zanoaga Oana, Burz Claudia, Ferracin Manuela, Raduly Lajos, Berindan-Neagoe Ioana
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, 400337, Romania; Research Center for Advanced Medicine-MedFUTURE, Department of Translational Medicine, "Iuliu Haţieganu" University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, 400337, Romania.
Transl Oncol. 2024 Jun;44:101951. doi: 10.1016/j.tranon.2024.101951. Epub 2024 Apr 1.
Lung cancer remains one of the leading causes of cancer-related deaths worldwide. It is classified into two main histological groups: non-small cell lung cancer (NSCLC) and small cell lung cancer. Improving the outcome of cancer patients could be possible by enhancing the early diagnosis. In the current study, we evaluated the levels of three microRNAs - miR-21-5p, miR-155-5p, and miR-181a-5p in tumor (TT) vs adjacent normal tissue (NT), as well as their expression levels in plasma and extracellular vesicles (EVs) from plasma in lung squamous cell carcinoma (LUSC) male patients vs healthy individuals as means to identify a panel of miRNAs that could serve as novel biomarkers for the diagnosis of LUSC in male patients. Matched paired tissue samples from male LUSC (n=40) patients were used for miRNA expression analysis. MiR-21-5p and miR-155-5p in tumor tissue were overexpressed, while underexpression of miR-181a-5p was observed in LUSC TT vs NT. These results were further validated in the TCGA LUSC dataset, considering 279 male samples. These alterations of miR-21-5p, miR-181a-5p, and miR-155-5p in tumor tissue are also present in plasma and plasma extracellular vesicles in LUSC male patients. In addition, ROC curves were performed to assess the sensitivity and specificity of different combinations of these miRNAs, confirming a high diagnostic accuracy for LUSC of up to 88 % in male subjects. The expression levels in tissue samples and the abundance in plasma and plasma EVs of the three miRNAs combined - miR-21-5p, miR-155-5p and miR-181a-5p - could be considered for further studies on biomarkers for the early detection of LUSC in male subjects.
肺癌仍然是全球癌症相关死亡的主要原因之一。它主要分为两个组织学类型:非小细胞肺癌(NSCLC)和小细胞肺癌。通过加强早期诊断有可能改善癌症患者的治疗结果。在本研究中,我们评估了三种微小RNA——miR-21-5p、miR-155-5p和miR-181a-5p在肺鳞状细胞癌(LUSC)男性患者的肿瘤组织(TT)与相邻正常组织(NT)中的水平,以及它们在血浆和血浆细胞外囊泡(EVs)中的表达水平,与健康个体进行比较,以确定一组可作为男性LUSC诊断新生物标志物的微小RNA。来自40例男性LUSC患者的配对组织样本用于微小RNA表达分析。肿瘤组织中的miR-21-5p和miR-155-5p过表达,而在LUSC的TT与NT中观察到miR-181a-5p表达下调。考虑到279个男性样本,这些结果在TCGA LUSC数据集中得到了进一步验证。LUSC男性患者的血浆和血浆细胞外囊泡中也存在肿瘤组织中miR-21-5p、miR-181a-5p和miR-155-5p的这些变化。此外,绘制ROC曲线以评估这些微小RNA不同组合的敏感性和特异性,证实男性受试者中LUSC的诊断准确率高达88%。miR-21-5p、miR-155-5p和miR-181a-5p这三种微小RNA在组织样本中的表达水平以及在血浆和血浆细胞外囊泡中的丰度,可用于进一步研究男性LUSC早期检测的生物标志物。